{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Ltd is Rated Strong Sell
Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 September 2025. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Oxygenta Pharmaceutical Ltd is Rated Strong Sell
Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 December 2025, providing investors with the latest insights into its performance and outlook.
Oxygenta Pharmaceutical Stock Hits 52-Week Low at Rs.52.1 Amidst Market Pressure
Oxygenta Pharmaceutical has reached a new 52-week low of Rs.52.1, marking a significant decline in its stock price amid a broader market downturn. The stock has underperformed its sector and the benchmark indices, reflecting ongoing challenges within the company and the pharmaceuticals sector.
Why is Oxygenta Pharma falling/rising?
On 15-Dec, Oxygenta Pharmaceutical Ltd witnessed a significant decline in its share price, closing at ₹55.61, down ₹4.54 or 7.55% from the previous session. This drop reflects ongoing weakness in the stock, which has underperformed both its sector and the broader market benchmarks over multiple time frames.
Oxygenta Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions
Oxygenta Pharma has experienced a revision in its market evaluation, reflecting shifts in its financial performance and market positioning. This adjustment highlights ongoing challenges within the Pharmaceuticals & Biotechnology sector, particularly for microcap companies facing operational and valuation pressures.
Oxygenta Pharmaceutical Sees Extraordinary Buying Interest Amid Upper Circuit Scenario
Oxygenta Pharmaceutical has attracted remarkable buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market behaviour signals a potential multi-day circuit scenario, reflecting strong demand despite recent price pressures and sector trends.
Oxygenta Pharmaceutical Ltd Surges 5% Today, Reaching Intraday High of Rs 63.87
Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with a significant stock increase today, reversing a two-day decline. Despite recent challenges, the stock has shown impressive long-term growth over five years. Current performance metrics indicate mixed technical signals, reflecting ongoing market sentiment and potential sector developments.
Oxygenta Pharmaceutical Ltd Surges 4.99% Today, Reaching Intraday High of Rs 63.99
Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with the stock rising significantly today, in contrast to a decline in the Sensex. Despite recent challenges, the stock has shown resilience over the past month, outperforming the index, while current trading indicates mixed trends in the short to medium term.
Why is Oxygenta Pharma falling/rising?
As of 10-Nov, Oxygenta Pharmaceutical Ltd's stock price is Rs 62.40, down 3.21%, and has underperformed significantly, losing 28.66% year-to-date. Despite some long-term gains, recent market conditions have negatively impacted its performance compared to the benchmark Sensex.
Oxygenta Pharmaceutical Ltd Faces Significant Selling Pressure with 35.03% Decline Over Three Months
Oxygenta Pharmaceutical Ltd is experiencing significant selling pressure, with consecutive losses leading to an 8.29% decline over two days. The stock has underperformed against the Sensex, showing a 35.03% drop over the past three months and trading below key moving averages, indicating ongoing challenges in the market.
How has been the historical performance of Oxygenta Pharma?
Oxygenta Pharma experienced significant sales growth, reaching 109.30 Cr in March 2025, but faced rising expenditures leading to negative operating profit of -10.00 Cr and worsening profitability metrics. Total liabilities increased to 72.62 Cr, with negative shareholder's funds at -25.02 Cr, indicating ongoing financial distress despite a slight improvement in cash flow from operations.
Are Oxygenta Pharma latest results good or bad?
Oxygenta Pharmaceutical's latest Q2 FY26 results are concerning, showing a net loss of ₹6.11 crores and a 69.42% decline in revenue, indicating significant operational challenges and a deteriorating financial position. The company faces severe structural issues, a negative net worth of ₹25.02 crores, and reliance on external funding, raising doubts about its long-term viability.
Oxygenta Pharmaceutical Q2 FY26: Mounting Losses Signal Deepening Crisis
Oxygenta Pharmaceutical Limited (formerly S S Organics Ltd.) reported a devastating second quarter for FY2026, with net losses ballooning to ₹6.11 crores—a 349.63% deterioration from the previous quarter's loss of ₹2.15 crores and a 349.26% decline from the ₹1.36 crore loss posted in Q2 FY25. The micro-cap pharmaceutical manufacturer, with a market capitalisation of ₹247.00 crores, saw its shares plunge 4.25% to ₹64.00 following the dismal results, extending a brutal downtrend that has seen the stock crash 52.06% from its 52-week high of ₹133.50.
Why is Oxygenta Pharma falling/rising?
As of 06-Nov, Oxygenta Pharmaceutical Ltd's stock price is at 67.44, having increased by 1.86% today and 9.16% over the past week, outperforming its sector. However, its year-to-date performance is negative at -22.90%, indicating longer-term challenges despite strong recent gains.
When is the next results date for Oxygenta Pharma?
Oxygenta Pharma will announce its results on 07 November 2025.
Why is Oxygenta Pharma falling/rising?
As of 28-Oct, Oxygenta Pharmaceutical Ltd is currently priced at Rs 63.88, reflecting a recent positive trend with a 9.57% gain over three days, but it has declined 26.97% year-to-date. Despite outperforming its sector recently, the stock shows mixed signals regarding future performance due to decreased investor participation and negative monthly performance.
Why is Oxygenta Pharma falling/rising?
As of 27-Oct, Oxygenta Pharmaceutical Ltd's stock price is Rs 62.38, up 5.0% today, but it has declined 10.89% over the past month and 28.68% year-to-date. Despite today's gains, investor participation has decreased significantly, indicating potential challenges in regaining confidence.
Oxygenta Pharmaceutical Ltd Surges 5.00% Today, Achieves Total Return of 6.35% Over Two Days
Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with a 5.00% increase today, marking its second consecutive day of gains. Despite this short-term uptick, the stock has faced longer-term challenges, including significant declines over the past month and year-to-date, reflecting ongoing market volatility.
Why is Oxygenta Pharma falling/rising?
As of 23-Oct, Oxygenta Pharmaceutical Ltd's stock price is Rs 58.30, down 4.99% and has fallen 11.6% over the last three days. The stock is underperforming significantly compared to the market, with a year-to-date decline of 33.35% against an 8.21% rise in the benchmark.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
